title: Somatostatin analogs regress endometriotic implants in rats by decreasing implant levels of vascular endothelial growth factor and matrix metaloproteinase 9.
abstract: OBJECTIVE
  To examine the effect of somatostatin analogs on surgically induced endometriosis in rat models.
  
  
  METHODS
  Endometrial tissue was implanted onto the abdominal peritoneum of 26 rats that were randomized into 3 groups. The rats in group 1(n = 9) were subcutaneously administered with 0.02 mg/kg/d of octreotide (a short-acting analog)for 28 days . The rats in group 2 (n = 8) were subcutaneously injected with 20 mg/kg of a single dose of a long-acting analogue lanreotide The rats in group 3 were given no medication and served as controls (n = 9).
  
  
  RESULTS
  Mean volume and histologic score of implants in groups 1 (P < .01 and P < .05, respectively) and 2 (P < .01and P < .05, respectively) were significantly lower than that in group 3. There were significant reductions in vascular endothelial growth factor (VEGF) and matrix metalloproteinase 9 (MMP-9) immunoreactivities in group 1 (0.67 ± 0.50 and 1.22 ± 0.44, respectively; both P < .01) and group 2 (0.71 ± 0.48 and 0.86 ± 0.69, respectively; both P < .01) when compared with the control group (1.78 ± 0.83 and 2.11 ± 0.78, respectively).
  
  
  CONCLUSIONS
  Somatostatin analogs has regressed significantly the size of the endometriotic implants and caused atrophy of these lesions in rats by decreasing explant levels of VEGF and MMP-9.
authors.affiliation: Department of Obstetrics and Gynecology, Bezmialem Vakif University, School of Medicine, Istanbul, Turkey. sevketosman@gmail.com
authors.forename: Osman
authors.initials: O
authors.lastname: Sevket
authors.forename: Asli
authors.initials: A
authors.lastname: Sevket
authors.forename: Taner
authors.initials: T
authors.lastname: Molla
authors.forename: Nur
authors.initials: N
authors.lastname: Buyukpınarbasılı
authors.forename: Omer
authors.initials: O
authors.lastname: Uysal
authors.forename: Bulent
authors.initials: B
authors.lastname: Yılmaz
authors.forename: Banu
authors.initials: B
authors.lastname: Dane
authors.forename: Sefa
authors.initials: S
authors.lastname: Kelekcı
mesh_terms: D000818:Animals; D001284:Atrophy; D004195:Disease Models, Animal; D015536:Down-Regulation; D004715:Endometriosis / Q000201:enzymology / Q000473:pathology / Q000517:prevention & control*; D004717:Endometrium / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology / Q000637:transplantation; D005260:Female; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D015282:Octreotide / Q000494:pharmacology*; D010456:Peptides, Cyclic / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000494:pharmacology; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
chemical_list: D010456:Peptides, Cyclic; D042461:Vascular Endothelial Growth Factor A; C467498:vascular endothelial growth factor A, rat; C060347:lanreotide; D013004:Somatostatin; D020780:Matrix Metalloproteinase 9; C572337:Mmp9 protein, rat; D015282:Octreotide